Novartis: big in Japan
(CercleFinance.com) - Novartis announces that it has received a string of approvals from the Japanese Ministry of Health for five new products, which it says offer Japanese patients a wide range of new treatment options.
These approvals include Tabrecta in non-small cell lung cancer, Entresto in chronic heart failure, Mayzent in secondary progressive multiple sclerosis, and Enerzair and Atectura in different forms of asthma.
The Swiss pharmaceutical group says that these approvals in Japan come alongside seven others obtained in Japan since the beginning of 2020, including Zolgensma in spinal muscular atrophy in March.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
These approvals include Tabrecta in non-small cell lung cancer, Entresto in chronic heart failure, Mayzent in secondary progressive multiple sclerosis, and Enerzair and Atectura in different forms of asthma.
The Swiss pharmaceutical group says that these approvals in Japan come alongside seven others obtained in Japan since the beginning of 2020, including Zolgensma in spinal muscular atrophy in March.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.